PEPTIDES FOR MUSCLE GROWTH

Direct anabolic peptides like IGF-1 LR3 act on the IGF-1 receptor and drive skeletal-muscle hypertrophy in rodent models. Growth-hormone secretagogues like CJC-1295 plus Ipamorelin raise endogenous GH and IGF-1 pulses. BPC-157 and TB-500 act on tissue repair rather than direct hypertrophy, but accelerate recovery between training stress events. No clean head-to-head human RCT compares these compounds for hypertrophy.

The Wolverine stack pairs BPC-157 (angiogenesis, VEGF, NO, growth-hormone-receptor upregulation) with TB-500 (G-actin sequestration, cell migration). The two mechanisms are complementary rather than competitive. Animal-model evidence is the basis for combining them in community protocols. No published RCT validates the specific combination in humans. See /vs/bpc-157-vs-tb-500 for the full comparison.

Growth-hormone secretagogue references (CJC-1295, Ipamorelin, GHRP-2, GHRP-6, Hexarelin, and adjacent GH-axis analogs) are prohibited at all times by the World Anti-Doping Agency (WADA Prohibited List, Section S2 Growth Factors) for athletes in tested sport. See the WADA Prohibited List (wada-ama.org/en/prohibited-list) or peppudex.com/reports/regulatory-status-matrix for jurisdiction detail. Research-grade reference compounds are sold for in-vitro laboratory use only and are distinct from any approved prescription drug category.

Anabolic-androgenic steroids are testosterone derivatives that bind androgen receptors and drive direct protein synthesis. Research peptides act through different receptors: growth-hormone secretagogues raise endogenous GH, IGF-1 LR3 binds the IGF-1 receptor, BPC-157 and TB-500 act on tissue-repair pathways. Mechanisms, side-effect profiles, and regulatory status are all different. Both classes are off-label for muscle growth in the United States.